Project Grant R03HL171423
Award Date
8/15/24
Completion Date
7/31/26
Dollars Obligated
$253K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This Project Grant award of $5,715,866 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop novel, transformative therapies that substantially reduce the burden of morbidity and mortality from progressive pulmonary fibrosis (PF). The multi-year program, which began in September 2024, focuses on investigating the transcriptomic, genetic, epigenetic, metabolic, and environmental signatures that contribute to the initiation and early...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research provides $695,421 to The Regents of the University of California, San Francisco (UCSF) to conduct research focused on reversing pathogenic remodeling in idiopathic pulmonary fibrosis (IPF). The key objectives are to define pro-reparative differentiation pathways in the fibroblast and stem cell compartments that can be leveraged as therapy, and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $153,117 to support a 5-year research project focused on improving hematopoietic stem cell (HSPC) transplantation outcomes. The goal is to investigate mechanisms of HSPC-niche cell crosstalk, specifically how HSPC-derived extracellular vesicles promote remodeling of bone marrow endothelial cells and migration of HSPCs. The...
This $758,539 Project Grant, awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The Leland Stanford Junior University, aims to identify the mechanistic pathways leading to the generation and release of dysfunctional mitochondria during pre-hematopoietic stem cell transplantation (HSCT) conditioning. The goal is to discover new therapeutic targets to prevent graft-versus-host disease (GVHD), a leading cause of non-relapse mortality following...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $146,876 to the Coriell Institute for Medical Research to develop new methods for expanding functional hematopoietic stem cells (HSCs) from cryopreserved umbilical cord blood (UCB) samples. The project aims to optimize an approach using PPAR-α agonists, which have been shown to significantly expand long-term functional UCB HSCs...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $721,826 to Childrens Hospital Medical Center in Cincinnati, Ohio to conduct research on the regulation of alveolar fibroblast function and its impact on alveolar development and capillary network formation. The research aims to elucidate the role of the transcription factor MEOX2 in governing the differentiation and functional changes of alveolar matrix and...
This $1,546,880 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the regulatory mechanisms governing myofibroblast differentiation in idiopathic pulmonary fibrosis (IPF). The primary objectives are to: 1) determine the "regulatory architecture" of open chromatin in myofibroblasts in IPF, 2) examine how expression levels of E-box transcription factors...
This federal Project Grant award of $301,840 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a research project titled "EPIC-LT: ELIMINATING PGD THROUGH INHIBITION OF CCR5 IN LUNG TRANSPLANTATION". The primary objectives are to: Measure the feasibility of recruiting lung transplant recipients for a pilot clinical trial of CCR5 inhibition to prevent primary graft dysfunction (PGD). Assess the safety and tolerability of the...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,193,262 to The Regents of the University of California, San Francisco to develop an adeno-associated virus-mediated SGPL1 gene therapy as a potential first-in-class treatment for idiopathic pulmonary fibrosis (IPF). The research aims to confirm the efficacy of this gene therapy in reducing lung fibrosis and downstream profibrotic signaling in mouse models and...